CuraTeQ Biologics s.r.o., a wholly owned step-down subsidiary of Aurobindo Pharma, has obtained marketing authorisation from UK's Medicines and Healthcare products Regulatory Agency (MHRA) for Dazublys™, its trastuzumab biosimilar version.
Earlier in July 2025, Dazublys™ has received the marketing authorisation in the European Union from the European Commission (EC).
This is CuraTeQ's fourth biosimilar to be approved by MHRA after the approval of Bevqolva™ in December 2024 and Zefylti™ in May 2025 and Dyrupeg™ in June 2025.
Dazublys™, Zefylti™, and Dyrupeg™ are also approved in the European Union.